These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 23453207)

  • 1. S3. Rituximab for ANCA-associated vasculitides: the French experience.
    Charles P; Guillevin L
    Presse Med; 2013 Apr; 42(4 Pt 2):534-6. PubMed ID: 23453207
    [No Abstract]   [Full Text] [Related]  

  • 2. S2. Rituximab for ANCA-associated vasculitis: the UK experience.
    Jayne D
    Presse Med; 2013 Apr; 42(4 Pt 2):532-4. PubMed ID: 23490639
    [No Abstract]   [Full Text] [Related]  

  • 3. S1. Rituximab for ANCA-associated vasculitis: the experience in the United States.
    Clain JM; Specks U
    Presse Med; 2013 Apr; 42(4 Pt 2):530-2. PubMed ID: 23477713
    [No Abstract]   [Full Text] [Related]  

  • 4. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
    Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X
    Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
    Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
    Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
    Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L;
    N Engl J Med; 2014 Nov; 371(19):1771-80. PubMed ID: 25372085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of ANCA-associated vascularitides].
    Guillevin L; Pagnoux C
    Presse Med; 2007 May; 36(5 Pt 2):922-7. PubMed ID: 17408912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab.
    Eriksson P
    J Intern Med; 2005 Jun; 257(6):540-8. PubMed ID: 15910558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rituximab to treat ANCA-associated vasculitis].
    Guillevin L; Mahr A
    Rev Med Interne; 2011 Oct; 32(10):591-3. PubMed ID: 21872370
    [No Abstract]   [Full Text] [Related]  

  • 10. Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis.
    Rutgers A; Kallenberg CG
    Curr Opin Rheumatol; 2012 May; 24(3):245-51. PubMed ID: 22410545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [ANCA-associated vasculitis].
    Holle JU
    Internist (Berl); 2015 Jan; 56(1):41-50; quiz 51-2. PubMed ID: 25502657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab therapy for Wegener's granulomatosis refractory to conventional treatment.
    Sánchez-Escuredo A; Núñez R; Ibernón M; Martínez E; López D; Navarro M; Bonet J; Ara J; Romero R
    Nefrologia; 2011; 31(4):502-4. PubMed ID: 21738261
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis: update.
    Santana AN; Woronik V; Halpern AS; Barbas CS
    J Bras Pneumol; 2011; 37(6):809-16. PubMed ID: 22241040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab for ANCA-associated vasculitides.
    Guillevin L
    Clin Exp Rheumatol; 2014; 32(3 Suppl 82):S118-21. PubMed ID: 24854382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Vasculitis management: discovery of antineutrophil cytoplasmic antibodies (ANCA)].
    Guillevin L
    Presse Med; 2007 May; 36(5 Pt 2):843-4. PubMed ID: 17449373
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
    Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L6. Eosinophilic granulomatosis with polyangiitis: future therapies.
    Moosig F
    Presse Med; 2013 Apr; 42(4 Pt 2):510-2. PubMed ID: 23453508
    [No Abstract]   [Full Text] [Related]  

  • 18. [Rituximab for the treatment of ANCA associated vasculitis: the future today?].
    Alba MA; Flores-Suárez LF
    Reumatol Clin; 2011 Dec; 7 Suppl 3():S41-6. PubMed ID: 22115869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab or cyclophosphamide in ANCA-associated renal vasculitis.
    Karassa FB
    N Engl J Med; 2010 Nov; 363(21):2073; author reply 2073-4. PubMed ID: 21083398
    [No Abstract]   [Full Text] [Related]  

  • 20. L52. Vasculitis treatment: is it time to change the standard of care for ANCA-associated vasculitis?
    Hoffman GS
    Presse Med; 2013 Apr; 42(4 Pt 2):643-50. PubMed ID: 23474045
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.